LoriH.PaiMD

Oncology • Boston, MA

Thoracic Cancer

Physician

Join to view full profile

Dr. Pai is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Pai's full profile

Already have an account?

Office
800 Washington St
Boston, MA 02111
Phone+1 617-636-8148

Fax+1 203-863-4738

Education & Training

Tufts Medical CenterFellowship, Hematology and Medical Oncology, 2011 - 2014
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 2003 - 2005
Harvard Medical SchoolClass of 2001

Certifications & Licensure

HI State Medical License 2024 - 2026
MA State Medical License 2013 - 2026
NY State Medical License 2004 - 2012
CT State Medical License 2005 - 2008
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy Start of enrollment: 2022 Jan 03
TERMINATED
PHASE2
NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer Start of enrollment: 2020 Nov 24
Active, not recruiting
Not Applicable
Roles: Contact, Principal Investigator

Publications & Presentations

PubMed

Real-world comparative outcomes of EGFR-TKIs for first-line treatment of EGFR+ metastatic non-small-cell lung cancer.
Kibum Kim, Sakil Syeed, Trang Au, Amber Diaz, Matthew B Schabath
Cancer Treatment and Research Communications. 2025-03-13
Role of circulating tumor DNA in early-stage triple-negative breast cancer: a systematic review and meta-analysis.
Diana Zhang, Shayesteh Jahanfar, Judy B Rabinowitz, Joshua Dower, Fei Song
Breast Cancer Research. 2025-03-12
Combined programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 blockade in an international cohort of patients with acral lentiginous melanoma.
Erin McGillivray, Karam Ashouri, Eftychia Chatziioannou, Jesús Antonio Ocejo Gallegos, Jabra Zarka
The British Journal of Dermatology. 2025-01-24

Press Mentions

Neuroimmunological Adverse Events Associated with Immune Checkpoint Inhibitor: A Retrospective, Pharmacovigilance Study Using FAERS DatabaseJanuary 9th, 2021